Qurient Co. Ltd (115180) - Total Liabilities

Latest as of September 2025: ₩6.81 Billion KRW ≈ $4.61 Million USD

Based on the latest financial reports, Qurient Co. Ltd (115180) has total liabilities worth ₩6.81 Billion KRW (≈ $4.61 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 115180 cash flow metrics to assess how effectively this company generates cash.

Qurient Co. Ltd - Total Liabilities Trend (2014–2024)

This chart illustrates how Qurient Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Qurient Co. Ltd (115180) asset resilience to evaluate the company's liquid asset resilience ratio.

Qurient Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Qurient Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Minerals 260 Ltd
AU:MI6
Australia AU$16.95 Million
Varroc Engineering Limited
NSE:VARROC
India Rs30.51 Billion
Eczacibasi Yatirim Holding Ortakligi AS
IS:ECZYT
Turkey TL573.72 Million
Zhejiang Changhua Auto Parts Co Ltd
SHG:605018
China CN¥678.48 Million
Aucma Co Ltd
SHG:600336
China CN¥4.92 Billion
Qingdao Eastsoft Communic Tech
SHE:300183
China CN¥428.47 Million
People & Technology Inc
KQ:137400
Korea ₩1.14 Trillion
SMU S.A
SN:SMU
Chile CL$1.67 Trillion

Liability Composition Analysis (2014–2024)

This chart breaks down Qurient Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Qurient Co. Ltd market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 6.32 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.14 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.12 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Qurient Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Qurient Co. Ltd (2014–2024)

The table below shows the annual total liabilities of Qurient Co. Ltd from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 ₩7.97 Billion
≈ $5.40 Million
+35.53%
2023-12-31 ₩5.88 Billion
≈ $3.99 Million
+79.65%
2022-12-31 ₩3.28 Billion
≈ $2.22 Million
-7.61%
2021-12-31 ₩3.55 Billion
≈ $2.40 Million
-16.46%
2020-12-31 ₩4.24 Billion
≈ $2.88 Million
+35.36%
2019-12-31 ₩3.14 Billion
≈ $2.12 Million
-17.30%
2018-12-31 ₩3.79 Billion
≈ $2.57 Million
+230.89%
2017-12-31 ₩1.15 Billion
≈ $776.40K
-39.40%
2016-12-31 ₩1.89 Billion
≈ $1.28 Million
+96.17%
2015-12-31 ₩963.76 Million
≈ $653.12K
-97.09%
2014-12-31 ₩33.11 Billion
≈ $22.44 Million
--

About Qurient Co. Ltd

KQ:115180 Korea Biotechnology
Market Cap
$881.75 Million
₩1.30 Trillion KRW
Market Cap Rank
#9679 Global
#276 in Korea
Share Price
₩37300.00
Change (1 day)
-5.09%
52-Week Range
₩9950.00 - ₩50900.00
All Time High
₩50900.00
About

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as … Read more